Search - tctmd.com

Displaying 81 - 100 of 174

Sort: Relevancy | Date

News Daily News

CVD, Diabetes Spike in Acute Phase of COVID-19

Todd Neale

July 19, 2022

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

L.A. McKeown

June 23, 2022

News Daily News

Too Much Sitting Linked to Bad Outcomes Around the Globe: PURE

Michael O'Riordan

June 17, 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

Michael O'Riordan

February 18, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Opinion Editor's Corner AHA 2021

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

Shelley Wood

November 08, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Daily News HFSA 2021

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

Michael O'Riordan

September 15, 2021

News Daily News

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

Alexandra Dangas

September 06, 2021

News Daily News

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Yael L. Maxwell

July 09, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Daily News

Sleep Apnea Awareness, Treatment May Improve Some CVD Outcomes: AHA

L.A. McKeown

June 23, 2021

News Daily News

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

Michael O'Riordan

June 16, 2021

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Daily News

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Shelley Wood

May 27, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Daily News

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Michael O'Riordan

May 11, 2021

Advertisement

CVD, Diabetes Spike in Acute Phase of COVID-19

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

Too Much Sitting Linked to Bad Outcomes Around the Globe: PURE

Dapagliflozin Boosts Health Status Across LVEF Range

Good News and Bad for High-Intensity Statin Use in ASCVD

FDA Approves Empagliflozin for Treatment of HFpEF

Statin Intolerance Overestimated—Only ‘Small Number’ Get Side Effects: Meta-analysis

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

AHA 2021 Tackles AF Triggers, Watchful Waiting in AS, Data Overload, and More

November 2021 News Roundup

In HF and Diabetes, Mobile Health App Modestly Boosts Physical Activity

As CDC Moves to Update Contraception Guidance, Cardiologists Should Take Note

FDA Approves Finerenone for Adults With CKD and Type 2 Diabetes

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Sleep Apnea Awareness, Treatment May Improve Some CVD Outcomes: AHA

Stopping Statins Ups CVD and Mortality Risks in Pill-Burdened Seniors

June 2021 News Roundup

Dapagliflozin US Cost-effectiveness Data Expose Barriers to HF Care

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Finerenone Cuts CV Events in CKD Patients With Diabetes: FIGARO-DKD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content